Statin use and its implications on survival and disease progression in the European MultiPartner idiopathic pulmonary fibrosis registry (EMPIRE) - PubMed
5 hours ago
- #IPF
- #Statin
- #Survival Analysis
- Statin use was investigated in the European MultiPartner IPF Registry (EMPIRE) for its association with survival and disease progression in idiopathic pulmonary fibrosis (IPF) patients.
- 27.7% of the 2,669 selected patients reported statin use, showing longer unadjusted overall survival (OS) compared to non-users (HR 0.79, p < 0.001).
- After adjusting for covariates like age, baseline FVC, and cardiovascular disease, no significant difference in OS was found between statin users and non-users (HR 0.90, p = 0.16).
- Subgroup analyses showed significant unadjusted OS benefits in patients not receiving antifibrotics (HR 0.64, p < 0.001), but this was not significant after adjustment.
- No meaningful differences in event-free survival (EFS) were observed based on statin treatment, with or without antifibrotics.
- The study concluded that statin treatment was not significantly associated with improved or worsened outcomes in IPF patients in the EMPIRE registry.